Dupilumab for early and long-term symptom relief and immune changes in prurigo nodularis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, real-world study following adults with moderate-to-severe prurigo nodularis who start treatment with dupilumab. Patients are enrolled in the BioDay registry and some may consent to provide samples to the UMC Utrecht Biobank for translational analyses. The study will track early and long-term clinical outcomes (symptoms and lesion changes) alongside immune markers to understand how dupilumab acts in routine clinical care. Findings aim to link clinical response with immune changes to help personalize treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients with moderate-to-severe prurigo nodularis starting dupilumab treatment

Exclusion Criteria:

* Unwilling to participate in the BioDay registry
* (For translational endpoints only) Unwilling to participate in UMC Utrecht Biobank

Where it's running

• University Medical Center Utrecht
  Utrecht, Utrecht, Netherlands Recruiting

Study contacts

• Study coordinator: Marjolein de Bruin-Weller, Professor
• Email: m.s.debruin-weller@umcutrecht.nl
• Phone: 000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dupilumab for Major Depressive Disorder

  This study tests whether dupilumab can engage immune targets in adults with major depressive disorder to see if it can help with depressive symptoms.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07908563

• See if IBI3027 works as well as Dupilumab for moderate to severe atopic dermatitis

  This study tests whether IBI3027 can help people with moderate to severe atopic dermatitis as effectively as Dupilumab injections.

  Recruiting Phase 3 Innovent Biologics (Suzhou) Co. Ltd. · Guangzhou, Guangdong · NCT07754786

• Dupilumab in COPD: Real-world Registry of Outcomes

  This registry tests how dupilumab works for COPD patients in everyday care and whether it lowers flare-ups and improves lung function and quality of life.

  Recruiting at 7 sites Sanofi · Indianapolis, Indiana and 6 other locations · NCT07612878

• Dupilumab added to standard COPD care after a flare-up

  This study tests whether adding dupilumab to usual COPD care after a severe flare requiring hospitalization can reduce the chance of another flare.

  Recruiting Phase 4 Regeneron Pharmaceuticals · Mullica Hill, New Jersey · NCT07587658

• Dupilumab's effect on anxiety and depression in moderate-to-severe atopic dermatitis

  This project will see if dupilumab reduces anxiety and depression in people with moderate-to-severe atopic dermatitis who are starting or recently started the medicine.

  Recruiting at 4 sites Sanofi · Doha and 6 other locations · NCT07467564

• Long-term follow-up of dupilumab treatment for COPD

  This project will follow adults with uncontrolled COPD and high blood eosinophils who start dupilumab in routine care to see if it is safe and improves symptoms and quality of life over 36 months.

  Recruiting at 28 sites Sanofi · Aix-en-Provence and 27 other locations · NCT07380711

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.